NeuroOne Medical Technologies 将来の成長

Future 基準チェック /26

NeuroOne Medical Technologiesは、10.5%と32.7%でそれぞれ年率10.5%で利益と収益が成長すると予測される一方、EPSはgrowで26.7%年率。

主要情報

10.5%

収益成長率

26.7%

EPS成長率

Medical Equipment 収益成長	12.7%
収益成長率	32.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	05 May 2025

今後の成長に関する最新情報

Recent updates

NeuroOne Medical Technologies: A Small-Cap Electrode Technology Play With Multiple Catalysts Ahead

Dec 10

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Dec 16

Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

Jul 25

Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

Apr 11

We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

Sep 15

NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet

Aug 03

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Jun 02

Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky

Dec 18

NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions

Nov 19

Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?

Sep 04

We're Not Very Worried About NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Rate

May 27

業績と収益の成長予測

NasdaqCM:NMTC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2027	16	-6	N/A	-5	1
9/30/2026	11	-8	N/A	-7	1
9/30/2025	8	-6	N/A	-5	1
12/31/2024	6	-7	-7	-7	N/A
9/30/2024	3	-12	-11	-11	N/A
6/30/2024	4	-12	-11	-11	N/A
3/31/2024	4	-13	-12	-12	N/A
12/31/2023	3	-13	-14	-13	N/A
9/30/2023	3	-12	-13	-13	N/A
6/30/2023	5	-10	-9	-9	N/A
3/31/2023	4	-9	-9	-9	N/A
12/31/2022	4	-9	-9	-8	N/A
9/30/2022	2	-10	-8	-8	N/A
6/30/2022	0	-11	-11	-11	N/A
3/31/2022	0	-11	-10	-10	N/A
12/31/2021	0	-11	-10	-9	N/A
9/30/2021	0	-10	-9	-9	N/A
6/30/2021	2	-8	-6	-6	N/A
3/31/2021	2	-12	-5	-5	N/A
12/31/2020	2	-11	-4	-4	N/A
9/30/2020	2	-14	-4	-3	N/A
6/30/2020	N/A	-14	-5	-5	N/A
3/31/2020	N/A	-9	-5	-5	N/A
12/31/2019	N/A	-10	-6	-6	N/A
9/30/2019	N/A	-7	-6	-5	N/A
6/30/2019	N/A	-8	-5	-5	N/A
3/31/2019	N/A	-7	-4	-4	N/A
12/31/2018	N/A	-6	-3	-3	N/A
9/30/2018	N/A	-7	N/A	-3	N/A
6/30/2018	N/A	-6	N/A	-2	N/A
3/31/2018	N/A	-6	N/A	-2	N/A
12/31/2017	N/A	-5	N/A	-2	N/A
9/30/2017	N/A	-4	N/A	-2	N/A
3/31/2017	N/A	-1	N/A	-1	N/A
12/31/2016	N/A	0	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NMTC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NMTC今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: NMTC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NMTCの収益 ( 32.7% ) US市場 ( 8.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: NMTCの収益 ( 32.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NMTCの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/05/07 00:47
終値	2025/05/07 00:00
収益	2024/12/31
年間収益	2024/09/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

NeuroOne Medical Technologies Corporation 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。2

アナリスト	機関
Alexander Nowak	Craig-Hallum Capital Group LLC
Jeffrey Cohen	Ladenburg Thalmann & Company

NeuroOne Medical Technologies 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

NeuroOne Medical Technologies Corporation Re-Affirms Earnings Guidance for the Full Year 2025

Price target decreased by 25% to US$2.00

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 27% to US$2.67

Consensus revenue estimates increase by 13%, EPS downgraded

Consensus revenue estimates increase by 13%

Recent updates

NeuroOne Medical Technologies Corporation to Report Q2, 2025 Results on May 13, 2025

NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

New major risk - Shareholder dilution

Chief Financial Officer recently bought US$100k worth of stock

NeuroOne Medical Technologies Corporation has completed a Follow-on Equity Offering in the amount of $8 million.

New major risk - Share price stability

NeuroOne Medical Technologies Corporation has filed a Follow-on Equity Offering.

NeuroOne Medical Technologies Corporation Accelerates Timeline of 510(K) Submission to FDA for the OneRF Trigeminal Nerve Ablation System to Treat Facial Pain

NeuroOne Medical Technologies Corporation Re-Affirms Earnings Guidance for the Full Year 2025

First quarter 2025 earnings released: EPS: US$0.058 (vs US$0.14 loss in 1Q 2024)

NeuroOne Medical Technologies Corporation to Report Q1, 2025 Results on Feb 12, 2025

NeuroOne Medical Technologies Corporation, Annual General Meeting, Feb 14, 2025

NeuroOne Medical Technologies Provides Nasdaq Non-Compliance Update Regarding Minimum Bid Price Requirement

NeuroOne Medical Technologies Corporation Auditor Raises 'Going Concern' Doubt

Full year 2024 earnings released: US$0.46 loss per share (vs US$0.65 loss in FY 2023)

NeuroOne Medical Technologies: A Small-Cap Electrode Technology Play With Multiple Catalysts Ahead

NeuroOne Medical Technologies Corporation to Report Q4, 2024 Results on Dec 17, 2024

Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.20 loss in 3Q 2023)

NeuroOne Medical Technologies Corporation to Report Q3, 2024 Results on Aug 14, 2024

NeuroOne Medical Technologies Corporation announced that it has received $2.650001 million in funding

NeuroOne Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Insufficient new directors

NeuroOne® Announces First in Human Ablations Completed with OneRF™ Ablation System

Neuroone Medical Technologies Corporation Receives Approval of ICD-10 Procedure Code for sEEG RF Ablation

Second quarter 2024 earnings released: US$0.11 loss per share (vs US$0.21 loss in 2Q 2023)

NeuroOne Medical Technologies Corporation to Report Q2, 2024 Results on May 14, 2024

Price target decreased by 25% to US$2.00

NeuroOne Medical Technologies Corporation Initiates Limited Commercial Launch of OneRF Ablation System

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

NeuroOne Medical Technologies Corporation to Report Q1, 2024 Results on Feb 13, 2024

NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 14, 2024

Chief Operating Officer recently bought US$105k worth of stock

Co-Founder notifies of intention to sell stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 27% to US$2.67

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

NeuroOne Medical Technologies Corporation Receives FDA 510(K) Clearance to Market its OneRF(TM) Ablation System

NeuroOne Medical Technologies Corporation to Report Q4, 2023 Results on Dec 14, 2023

NeuroOne Medical Technologies Corporation Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe

NeuroOne Medical Technologies Corporation Appoints Christopher R. Volker as Chief Operating Officer

NeuroOne Medical Technologies Corporation Provides Progress Update on FDA 510(k) Submission for OneRF™? Ablation System

Chief Financial Officer recently bought US$50k worth of stock

Consensus revenue estimates increase by 13%, EPS downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

NeuroOne Medical Technologies Corporation to Report Q3, 2023 Results on Aug 14, 2023

New major risk - Share price stability

Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

NeuroOne Medical Technologies Corporation Submits 510(K) Application to FDA for OneRF™ Ablation System

NeuroOne Medical Technologies Corporation Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery

Consensus revenue estimates increase by 13%

Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.19 loss in 2Q 2022)

NeuroOne Medical Technologies Corporation to Report Q2, 2023 Results on May 11, 2023

Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

Consensus revenue estimates decrease by 41%, EPS upgraded

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

NeuroOne Medical Technologies Corporation to Report Q1, 2023 Results on Feb 14, 2023

NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 16, 2023

Consensus revenue estimates increase by 154%

NeuroOne Medical Technologies Corporation Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeuroOne Successfully Completes Feasibility Study with its OneRF Ablation System

Price target decreased to US$2.63

NeuroOne Medical Technologies Corporation Receives U.S. Food and Drug Administration 510(K) Clearance to Market Its Evo sEEG System for Less Than 30 Day Use

We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeuroOne Medical Technologies Corporation Submits Special 510(k) to FDA for Evo sEEG Electrode

Consensus estimates of losses per share improve by 13%

NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet